CHM Fundamental's, page-26

Currently there is only one CAR-T approved by the FDA, CD19, used to treat blood cancer. So far there is no other CAR-T approved to treat any solid tumours which account for about 90% of all cancers.

Worldwide there is work underway to validate other targets, such as CD 21,22 and a few others plus CDH 17 to treat solid tumours.

IMU is testing its oncolytic virus CF 33 with a CD19 antigen - the first attempt to literally "crack" solid tumours. The virus is opening the tumour, CD 19 is signaled to the immune system and CAR-T plus the immune response kill the cancer.

As soon as either IMU's Vaxinia and CHECKvaxx or CHM's CDH 17 are successfully tested in humans I assume we will see IMU partnering with CHM to get a combo of CF33 and CDH 17. This week IMU announced huge progress as well as CHM and as both are run by almost the same people my assumptions aren't that out of this world.

Grabbed 100k shares at the close and will add more, hopefully for less. CHM's portfolio is fantastic, Brain cancer trials promissing and CDH 17 will enter the clinics hopefully soon. IMU / CHM know exactly to interpret mice results, IMU's clinical trials so far have delivered what the pre-clinical have suggested - therefore we can be very optimistic, in fact realistic, about a groundbreaking result. And not to forget IMU's saftey profile - 100% non - toxic. We can expect similar results with CDH 17, which has been stated for the pre-clinical already.

For a LTer with a few years patience this could be a huge winner, especially with that low MC of far less than $ 100m.

On a sour note, you guys have to put up with me from now on, LOL


GLTA